Genomic and Clinical Landscape of Metastatic HR+ Breast Cancers With ESR1 Alterations
Read it now on PracticeUpdate.com
Related Articles
Early Palliative Care May Increase QOL in Ovarian Cancer Decedents Near EOL
Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.
1369 Engineering approaches to exploit MHC-II presentation on lung cancer cells
Background Central to the success of immunotherapy is antigen presentation on Major Histocompatibility Class I and II (MHC-I and MHC-II).1 While much effort has been…
451 CD40L-4–1BB can stimulate tumor infiltrating lymphocyte ex vivo expansion from melanoma core biopsies
Background Tumor-infiltrating lymphocyte (TIL) expansion ex vivo is currently performed from surgically excised tumors in culture media containing Interleukin-2 (IL-2). Targeting antigen-presenting cells through CD40…
450 Pooled analysis of efficacy outcomes from early-phase trials of tumor infiltrating lymphocyte therapy in advanced melanoma
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) represents a promising strategy for the treatment of patients with advanced melanoma (MEL). In this study…
639 Phase I clinical trial of autologous gamma/delta-enriched chimeric antigen receptor (CAR)-T cells to target prostate stem cell antigen (PSCA) in patients with bone metastatic prostate cancer
Background Bone metastatic castration-resistant prostate cancer (M1b CRPC) remains a fatal disease with significant associated morbidity. PSCA is expressed in >90% of mCRPC, with limited…
Importance of predicting CML therapy failure
In this issue of Blood, Zhang et al1 propose a scoring system to predict the risk of treatment failure with tyrosine kinase inhibitors (TKIs) used in…
Funding Opportunities – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
Learn more about ASTRO research funding for early-career scientists in radiation oncology.
NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies
NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.
New NCI Grant to Advance Cancer Control Equity Research
Melissa Simon, MD, MPH Betina Yanez, PhD The $10 million grant will support the creation of a center focused on “Advancing Cancer Control Equity Research…
